SMA is the leading genetic cause of death of infants.

CSC files IND application to commence Phase We research for Spinal Muscular Atrophy California Stem Cell, Inc . and Families of Spinal Muscular Atrophy announced today that CSC provides filed an investigational brand-new drug program with the US Food and Drug Administration for acceptance to commence a Phase I safety study on a jointly-developed stem cell-derived motor neuron transplantation therapy for Spinal Muscular Atrophy Type I. SMA is the leading genetic cause of death of infants.

no stress during intimacy

CSC anticipates a Stage I safety study to begin in 2010.. CSC completes a string B financing round California Stem Cell, Inc. , a leading stem cell organization, announced that it has completed a Series B financing with personal investors round. The funding will enable the ongoing organization to support the advancement of its therapeutic products to human being clinical trials, and also the generation and distribution of its tools to assist in stem cell drug and research discovery. CSC is certainly a privately held company developing proprietary therapeutic products to take care of several neurodegenerative diseases, along with innovative stem cell-structured human cell items to facilitate research and conventional medication discovery.